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Abstract: Demographic indicators forecast that by 2050, the elderly will account for about 
one-third of the global population. Geriatric patients require a large number of medicines, and 
in most cases, these products are administered as solid oral solid dosage forms, as they are by 
far the most common formulations on the market. However, this population tends to suffer 
difficulties with swallowing. Caregivers in hospital geriatric units routinely compound in solid 
oral dosage forms for dysphagic patients by crushing the tablets or opening the capsules to 
facilitate administration. The manipulation of a tablet or a capsule, if not clearly indicated in 
the product labeling, is an off-label use of the medicine, and must be supported by documented 
scientific evidence and requires the patient’s informed consent. Compounding of marketed 
products has been recognized as being responsible for an increased number of adverse events 
and medical errors. Since extemporaneous compounding is the rule and not the exception in 
geriatrics departments, the seriousness and scope of issues caused by this daily practice are 
probably underestimated. In this article, the potential problems associated with the manipulation 
of authorized solid oral dosage forms are discussed.
Keywords: geriatric medicine, dysphagia, compounding, modified-release formulations, 
gastrointestinal tract toxicity
Introduction
Biodemography scientists have registered a significant lengthening of lifespan in the 
last 50 years. This is essentially due to the progress made in medicine and public 
health. Counterintuitively, the morbidity among elderly is continuously growing and 
the need for medical care increases with geriatric patient age.1 Also, considering the 
limits due to unpredictable happenings and the absence of reliable old records, the 
demographic trend draws a scary picture. It is estimated that, by 2050, people aged 65 
or more will account for about 25% of the total population of developed countries and 
15% of the people living in developing countries.2 This change in society composition 
will have strong repercussions in many societal policies, and a huge impact is expected 
in medical and health care system.
Medicine faces the great responsibility to deal with a continuously growing elderly 
population, and geriatric medicine is (and will be) the main actor of this revolution. 
A geriatric patient has many peculiar features that challenge the everyday work of 
clinicians, pharmacists, nurses, and health care providers (HCPs). Due to the aging 
process, the elderly show different pharmacokinetics and pharmacodynamics with 
respect to young adults,3 and the presence of different pathologic conditions (also 
known as comorbidity) obliges geriatric physicians to prescribe a large number of 
medicines, putting the patient in polypharmacotherapy. This situation further com-
plicates the scenario.4,5
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Difficulty in swallowing and dysphagia may be seen as 
a marginal problem, considering the acute and chronic dis-
eases that these patients have to deal with.6 Unfortunately, 
this is not the case. Dysphagia is most common among the 
elderly population because the aging process can negatively 
affect the oral, pharyngeal, and esophageal phases of the 
swallowing process. It can become worse by reduced saliva 
production.7,8 Difficulty in swallowing may be responsible for 
malnutrition, weight loss, and dehydration. At the same 
time, food and/or liquid entering the airways can provoke 
respiratory infections.9
In patients over 65 years of age, the prevalence of 
dysphagia ranges from 7% to 13%,10–12 a percentage that 
increases with age and if patients are affected by stroke, 
postoperative cognitive dysfunction, or neurodegenerative 
diseases such as Parkinson’s and dementia.9,13–17 Worthy of 
note is the fact that swallowing difficulties have been reported 
in about 50% of patients in nursing homes.18
Since the elderly patients are intrinsically predisposed 
to dysphagia and the number of elderly is increasing, the 
number of dysphagic patients will increase in the near 
future. This global demographic trend, fueled by falling 
birth rates and the continuous increase in life expectancy, 
is now certain, and brings with it significant social distress 
and a variety of chronic disabilities that will challenge health 
care systems and increase the need for pharmacologic and 
surgical treatments.19,20
Elderly patients with dysphagia are between a rock and a 
hard place, because they require a large number of prescrip-
tions like other geriatric patients,4,5,21 but difficulties with 
swallowing or dysphagia limit or preclude the administration 
of solid oral dosage forms, which are by far the most common 
formulations on the market.22 The problem could easily be 
bypassed if all the active pharmaceutical ingredients (APIs) 
contained in marketed products were available in formula-
tions other than solid oral dosage forms. Unfortunately, this 
is not the case, and in clinics, compounding is a daily practice 
as caregivers dispense crushed tablets or opened capsules 
to facilitate the administration of solid oral dosage forms to 
dysphagic patients.23,24
The US Food and Drug Administration defines com-
pounding as
A practice in which a licensed pharmacist, a licensed phy-
sician, or, in the case of an outsourcing facility, a person 
under the supervision of a licensed pharmacist, combines, 
mixes, or alters ingredients of a drug to create a medication 
tailored to the needs of an individual patient.25
Tablet and capsule manipulation can include tablet split-
ting, tablet crushing, and capsule opening, followed by the 
dispersion/dissolution of the tablet material or capsule content 
(eg, powder or granules) in water, beverages, gels, or food 
to allow better deglutition.26 When deglutition is completely 
impaired, the solution, suspension, or low-viscosity gel is 
delivered directly into the stomach by an enteral tube. The 
manipulation of a tablet or a capsule can seem trivial and 
insignificant.27 On the contrary, this is absolutely untrue: 
compounding of marketed products has been recognized as 
responsible for adverse events and medical errors.28–32
Representative is the title of a paper recently published by 
Verrue et al33 on tablet splitting “Tablet-splitting: a common 
yet not so innocent practice”. This sentence resumes quite 
well what happens in the everyday nursing practice. In fact, 
tablet splitting is, most of the time, an off-label use of the 
medicinal product and, even if it can be considered a priori 
safer than tablet crushing, it can have a negative impact on 
therapy outcome.
Before reaching the market, a medicinal product is care-
fully evaluated for its safety and efficacy through clinical 
trials, and all the technical data are reviewed and evaluated 
by the appropriate regulatory agency. Obviously, safety and 
efficacy are guaranteed if the product is used on-label, that 
is, by following the information reported in its labeling that 
includes product information leaflet and summary of the 
product characteristics. From the legislative point of view, 
the manipulation of a marketed formulation is defined as an 
off-label use of the drug. In fact, when a medicinal product is 
approved by the regulatory authorities, it can be administered 
to treat the diseases listed in the product labeling at the speci-
fied dose regimens and route of administration. This applies 
to the dosage form as well. Any manipulation of an approved 
medicinal product, such as by tablet splitting or crushing, or 
change in the administration route from oral to intragastric 
is, if not specified in the product information leaflet and 
summary of the product characteristics, an off-label use of 
the medicine. In these circumstances, the prescriber, the 
pharmacist, and the nurse may become legally responsible 
for any adverse effect resulting from taking the medicine.34
Compounding can affect the biopharmaceutical features of 
the product and its therapeutic outcome, resulting in an increased 
probability of adverse reactions for the patient.35 Patient risk 
is particularly important for APIs with a narrow therapeutic 
window, for drugs that are irritant to the gastrointestinal tract 
(GIT) mucosa, for drugs formulated in modified-release solid 
oral dosage forms, and for any product that is hormonal or 
steroid-based, cytotoxic, and teratogenic.36,37 For this reason, 
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the act of manipulating a solid dosage form should be under-
taken only if is impossible to give the medicine by an alternative 
route, or in a different licensed formulation.38
Given the threats associated with the practice of com-
pounding marketed medicinal products and its wide use for 
dysphagic patients in hospital geriatric units and home care, 
we believe that the risks for the patients and the ethical and 
legal issues connected to these procedures are underestimated 
and worthy of discussion.
This review focuses on concerns related to the manipula-
tion of medicinal products and concentrates its attention on 
biopharmaceutical/pharmacokinetics issues and GIT toxicity 
that may derive from this practice.
Biopharmaceutical considerations
Biopharmaceutics has a fundamental role in rationalizing 
and improving medicinal product performances and 
should be taken into consideration when compounding 
is contemplated.
Once a solid dosage form is administered orally to patients, 
the API has to be released and/or dissolved from the dosage 
form to the body fluids in order to be absorbed and distributed 
in the various organs and tissues. Virtually, no API possesses 
adequate characteristics to be administered on its own to 
patients, and its formulation in an adequate dosage form is 
needed. During the formulation step, an API is combined with 
different excipients and, with the aid of ad hoc technologic pro-
cedures, is shaped into the final medicinal product that has the 
required features for administration through the chosen route. 
The API can be formulated in a variety of dosage forms to 
obtain medicinal products with the desired consistency: solid 
(tablets, capsules, granules), semisolid (creams, ointments), 
or liquid. Solid dosage forms are the leading formulations 
on the market, and of these, .60% of APIs intended for oral 
administration are formulated as tablets and capsules.2,22
The oral route is highly preferable because patients can 
take the medicine themselves and, accordingly, it is associ-
ated with superior patient compliance and adherence. Solid 
dosage forms are also preferred by pharmaceutical companies 
because not only does the API stability tend to be higher in 
the solid state but also they cost much less to manufacture 
than the parenteral forms. Thus, solid dosage forms are the 
first choice for oral administration.22
The predominance of solid oral dosage forms, especially 
tablets and capsules, is the leading cause of potential issues 
in dysphagic patients. In fact, when administration through 
a different route is not possible and/or a different formulation 
is not available, the physician and the pharmacist face an 
important decision: should they prepare an ad hoc formulation 
in the hospital pharmacy or in an accredited laboratory, or 
should they manipulate the commercial formulation? Obvi-
ously, the best choice is to set up an ad hoc formulation, but 
this is not always possible since some APIs, especially those 
most recently approved, are not available in bulk. At the 
moment, the compounding of marketed medicinal products 
is the most common method for administering medication 
to dysphagic patients in hospitals and clinics, but the safety 
risks it poses have been largely underestimated.23,39,40
Crushing a solid dosage form in a mortar cannot be 
considered satisfactory from the point of view of repro-
ducibility and quality control. API particle size should 
be measured to guarantee at least the reproducibility of 
the manipulation procedure, but the presence of excipients 
makes the measurement challenging.41 API particle size has 
a direct relation to the dissolution rate and apparent solubil-
ity, and this correlation is particularly significant for low 
water-soluble compounds.42 Because of this, different particle 
sizes or particle size distributions generate diverse plasmatic 
curves and pharmacologic effects.43
Today, the presence of many modified-release formula-
tions in the market makes the decision “whether to crush 
a tablet or not” more difficult and much more dangerous. 
So, compounding should only be recommended by HCPs 
with sufficient knowledge of biopharmaceutics and the 
proprietary information about the technology used to pre-
pare the tablet or capsule. In fact, the first step for assessing 
the actual risks for the patient is to distinguish between a 
conventional-release (also called immediate-release) and a 
modified-release dosage form.
Conventional-release dosage form compounding 
may generate faster absorption and higher bioavailability 
(Figure 1).44,45 These issues become more significant and 
extremely dangerous for the geriatric dysphagic patient in 
the case of drugs with a narrow therapeutic index, such as 
warfarin, carbamazepine, digoxin, lithium, and theophylline, 
for which small changes in systemic concentration can lead 
to significant changes in pharmacodynamics.46 Additional 
problems may come from the imprecision of the dose, the 
reduced stability in solution, and the mixing with food, bever-
ages, or viscous gels to facilitate swallowing.
While the manipulation of conventional-release medi-
cations presents dangers, even greater risk is posed by 
compounding of modified-release dosage forms, which con-
siderably affects the product biopharmaceutics with harmful 
consequences for the patient. In general, the compounding 
of modified-release dosage forms is not recommended and 
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should be highly discouraged.47,48 In these dosage forms, 
compounding can strongly alter not only the amount of API 
released over time but also its release site, affecting its effi-
cacy and toxicity potential. Useful resources in this regard are 
“Oral Dosage Forms That Should Not Be Crushed 2015”48 
and the “Don’t Rush to Crush” handbook.49
In the case of prolonged-release oral solid medications, 
which are designed to release the API over an extended 
period of time, administration of a crushed form results in 
rapid absorption of the entire dose with adverse outcomes 
for the patient.36,50 Enteric-coated formulations of acid-labile 
APIs are designed to pass through the stomach intact and 
deliver the drug in the intestines. Crushing the medications 
subverts the intention of the formulators because the drug is 
then inactivated by gastric acid.51,52
With the availability of many modified-release solid oral 
dosage forms on the market, the “to crush or not to crush” 
dilemma is extremely critical. In fact, albeit a recent European 
Medical Agency guideline states, 
If applicable, specific recommendations should be provided 
to ensure optimum conditions of use (eg, instructions not 
to chew or crush tablets, etc),
most of the marketed modified-release formulations do not 
have the “not to chew or crush” recommendation.53
Issues connected to the compounding of a solid oral dos-
age form are manifold, but “dose dumping” is certainly the 
most serious consequence, since it presents the highest risk 
of morbidity and mortality for the patient. Dose dumping 
can be defined as 
an unintended, rapid drug release of the entire amount or a 
significant fraction of the active substance contained in a 
modified release dosage form.54
As an example, we can briefly mention the story of an 
83-year-old female who died after 3 weeks of chewing rather 
than swallowing the intact prolonged-release diltiazem 
capsule, because she found it difficult to swallow.55 In another 
case study, Schier et al50 reported the death of a woman after 
repeated daily administration of crushed prolonged-release 
nifedipine tablet through a nasogastric tube. Her death was 
ascribed to severe hypotension caused by high plasma con-
centration of nifedipine generated by the immediate release of 
the entire 90 mg dose (ie, dose dumping), which instead was 
formulated for release over an extended period of time.
However, some modified-release dosage forms have been 
designed to allow compounding. In a recent study, healthy 
subjects were administered intact or crushed capsules con-
taining microencapsulated oxycodone or immediate-release 
oxycodone tablets.56 Once the capsule is opened and the 
microparticles are crushed, the medicine remains bioequiva-
lent with the capsule swallowed intact (Figure 2): this makes 
the formulation suitable for compounding for dysphagic 
patients. On the contrary, crushed modified-release tablets 
become bioequivalent to the powder of the immediate-release 
oxycodone (Figure 2).
As is evident, not all solid dosage forms are suitable for 
splitting or crushing. But even when compounding is permis-
sible, human error by HCPs may dissipate the product and 
alter the dose administered, which can have serious clinical 
consequences, especially for APIs with a narrow therapeutic 
index.33,57 Even though the problem of oral drug therapy in 
geriatric dysphagic patients is not new, most scientists in 
academia and industry do not seem very sensitive to this 
issue. In a recent literature search, Messina et al58 evidenced 
the complete absence of scientific publications addressing 
the age appropriateness of medicinal products for the elderly. 
Regulatory agencies in North America and Europe are 
slowly moving the first step toward the elaboration of ad hoc 
strategies for the development of geriatric medicines. Unfor-
tunately, no guidelines on the adequacy of dosage forms to 
geriatric patients are available at the moment.59
Damage to patient GIT
Drug toxicity in the GIT is a common and important medical 
problem linked to extemporaneous compounding that can 
affect part or all of the GIT, with consequences ranging from 
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Figure 1 Median plasma concentrations of clopidogrel metabolite SR26334 following 
administration of whole or crushed 300 mg clopidogrel tablet.
Notes: The crushed tablet has been administered through a nose-gastric tube. 
Reproduced from Zafar MU, Farkouh Me, Fuster v, Chesebro JH. Crushed 
clopidogrel administered via nasogastric tube has faster and greater absorption than 
oral whole tablets. J Interv Cardiol. 2009;22(4):385–389, with permission from John 
wiley and Sons. Copyright 2009.44
Abbreviations: AUC, area under the curve; conc, concentration.
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minor pathologies such as drug-induced diarrhea to perfo-
ration or fatal hemorrhage.60 The morbidity and associated 
medical costs due to drug-induced GIT toxicity, as well as 
the mortality that may ensue, are probably underestimated.
A number of APIs, including ferrous sulfate,61 
bisphosphonates,62 potassium chloride,63 nonsteroidal anti-
inflammatory agents (NSAIDs),64 and tetracycline,65 have 
been identified as being responsible for GIT mucosal injuries. 
Sample endoscopic and microscopic views of GIT mucosae 
damaged by NSAIDs are shown in Figure 3.
To provide protection from these APIs, formulators 
use gastro-resistant enteric coatings made of polymers that 
remain intact in the stomach but dissolve and release the 
API in the more alkaline pH of the small intestine. Enteric 
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Figure 2 Left side: (A) intact microspheres (40 mg) obtained by empting one capsule of Deterx®; (B) crushed microspheres (40 mg) from one capsule of Deterx; 
(C) OxyContin® tablet intact (40 mg); (D) Oxycontin tablet crushed (40 mg); (E) two 20 mg intact immediate-release oxycodone tablets; (F) powder from two crushed 
immediate-release oxycodone tablets. Right side: mean plasma concentration–time curve profiles generated by the administration of intact and crushed Deterx compared 
with crushed immediate-release oxycodone (upper figure); mean plasma concentration–time curve profiles generated by the administration of intact and crushed Oxycontin 
compared with crushed immediate-release oxycodone (lower figure). Reproduced from Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the effect of 
tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–2151, by 
permission of Oxford University Press.56
Figure 3 Sample endoscopic and microscopic views of gastrointestinal tract mucosae damaged by NSAIDs.
Notes: (A) Endoscopic view of a stricture in the cecum of the colon in a patient after long-term NSAID use. The stricture has resulted in significant narrowing of colonic 
lumen. Such diaphragms have also been reported to occur in the small intestine. (B) Histologic section from a colonic biopsy showing a moderate inflammatory infiltrate 
in the lamina propria, mild lymphocytic infiltration of the glandular epithelium, and scattered eosinophils. Adapted by permission from Macmillan Publisher Ltd: Nat Clin 
Pract Gastroenterol Hepatol, Pusztaszeri MP, Genta RM, Cryer BL, Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations, 2007;4(8):442–453, 
copyright 2007.74
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.
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coatings not only serve to prevent stomach irritation but 
also make it possible to delay the release of APIs that are 
inactivated by the stomach contents, or to delay the onset of 
action at a specific site within the GIT.
Gastrointestinal symptoms resulting from either pre-
scribed medications or over-the-counter drugs are frequently 
encountered in geriatric practice. The manipulation of solid 
oral dosage forms to allow easy administration in dysphagic 
patients may increase the incidence and severity of adverse 
reactions involving the upper and lower GIT.
We subsequently discuss the APIs used in elderly patients 
that are responsible for GIT mucosal injuries, especially when 
the formulations are manipulated to allow swallowing.
Ferrous sulfate
Liabeuf et al61 reported a series of cases of ulceration of the 
oral mucosa linked to direct contact with ferrous sulfate in 
elderly patients, particularly when swallowing disorders 
were present, and advised that appropriate pharmaceutical 
formulations (eg, syrups) should be administered to at-risk 
patients. The mucosal damage caused by high local iron 
concentrations may be related to the formation of reactive 
oxygen species.66 Indeed, these species and free radicals have 
been implicated in mucosal alterations in gastric or intestinal 
injuries. The mucosal toxicity of ferrous sulfate has also been 
reported for the hypopharynx,67 the esophageal lumen,68 and 
the tracheobronchial tree.69 Mouth ulcerations and necrosis 
have been found after administering crushed tablets contain-
ing ferrous sulfate.61
Bisphosphonates
Bisphosphonates are a class of drugs developed over the 
past 20 years, primarily as antiresorptive agents for treat-
ing diseases related to bone remodeling. Soon after the 
release of alendronate, esophagitis and esophageal strictures 
were reported, and consequently, the drug labeling had 
to be changed. Subsequent endoscopic studies in healthy 
subjects showed that alendronate also caused gastric erosions 
and ulcers. Persistent mouth ulcerations have been reported 
by patients who sucked bisphosphonate tablets or let them 
dissolve in their mouth.70 Alendronate has the potential to 
cause ulcers within the esophagus and stomach, as well 
as occasional esophageal strictures. Although controlled 
trials have failed to demonstrate an increased incidence of 
these adverse events, several case studies and reports have 
described exudative and ulcerative esophagitis in patients 
who strictly adhered to recommended use directions, which 
resolved upon cessation of the therapy.62
Risedronate, a third-generation bisphosphonate, seems to 
be considerably less ulcerogenic and fibrogenic than alen-
dronate and may be a safer alternative for those unable to 
tolerate alendronate.62 In summary, given all the side effects 
described earlier for this class of drugs, it is recommended 
that tablets be swallowed whole, and are never split, chewed, 
or crushed, even in the case of dysphagic patients.
Potassium chloride
Drug-induced esophagitis caused by potassium chloride 
is usually present at the junction of the middle and distal 
thirds of the esophagus above the level of an enlarged heart 
compressing the distal esophagus. This compound can also 
lead to the development of strictures, most frequently at or 
above the level of an enlarged left atrium.63
Potassium chloride causes small bowel ulceration as a 
result of local vascular injury and thrombosis.71 Zografos 
et al72 analyzed 650 cases of drug-induced esophagitis from 
1970 to 2009 and reported that five deaths were related to 
potassium-induced esophageal injury. In particular, these 
patients developed fistulas from the esophagus into the aorta 
or left atrium, perforation into the mediastinum, bleeding 
ulcer, or inanition related to the esophageal stricture. The 
appearance of dysphagia or swallowing difficulties should 
be taken seriously for review of oral potassium therapy. It is 
recommended that oral potassium chloride supplements in 
liquid form should be administered to patients with cardio-
megaly and disorders of esophageal motility.71
Quite interestingly, Sinar et al73 performed a controlled 
multicenter investigation of the effects of oral potassium 
chloride supplements on the gastrointestinal mucosa. One 
hundred and twenty healthy men with no endoscopically 
apparent gastrointestinal lesions were confined to a research 
ward for 18 days. After the treatment was completed, endo-
scopic examinations of the esophagus, stomach, and duode-
num were performed and evaluated by specialists blinded to 
the particular treatment given. Mild to moderate gastrointes-
tinal irritation, characterized by erythema and edema, was 
found with similar frequency in all four treated groups.
Nonsteroidal anti-inflammatory drugs
Much attention has been focused on NSAIDs, the most 
commonly prescribed therapeutic class associated with GIT 
toxicity. In fact, NSAIDs can damage every level of the GIT 
from the esophagus to the large intestine.64,74
Among geriatric patients, the risk of NSAID-induced 
gastrointestinal complications due to long-term use may be as 
high as 15%.75 Although NSAIDs cause damage throughout 
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
20
4.
8.
28
 o
n 
02
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
247
Oral drug therapy in dysphagic elderly
the GIT, the predominant gastrointestinal site of injury is the 
stomach. NSAIDs produce two types of mucosal injury in 
the stomach.76 The first type of damage occurs shortly after 
the ingestion of the agent and seems to result primarily from 
local effects on the gastric mucosa (hyperemia, erosions, and/
or subepithelial hemorrhages). The second type of lesion 
induced by NSAIDs is gastric ulceration, and it is due to 
their systemic effect on prostaglandin synthesis through 
inhibition of cyclooxygenase. The clinical consequences of 
utmost concern among NSAID users are symptomatic gas-
trointestinal ulcers and ulcer complications such as severe 
gastrointestinal bleeding and perforation.
In contrast to what happens in the stomach, direct con-
tact of NSAIDs with the intestinal mucosa has a major role 
in the pathogenesis of NSAID toxicity in the small intes-
tine. Aspirin and nabumetone are rapidly absorbed in the 
stomach and duodenum and do not undergo enterohepatic 
recirculation. By contrast, compounds such as indomethacin 
that are metabolized through enterohepatic cycling are associ-
ated with greater intestinal toxicity, even when administered 
parenterally.77
NSAIDs can cause diffuse intestinal inflammation and 
increased intestinal mucosal permeability, a pathologic con-
dition known as NSAID enteropathy, clinically characterized 
by occult blood loss, iron deficiency, anemia, malabsorption, 
and protein loss.78
NSAID-induced lesions can develop in the healthy colon 
or at sites of preexisting colonic disease, such as diverticular 
disease or chronic inflammatory bowel disease. In some cases, 
NSAID therapy can reveal previously undiagnosed bowel 
disease. The most common pattern of NSAID-associated 
colonic damage is a nonspecific colitis.79
To prevent recurrent damage to GIT mucosae, par-
ticularly at the esophageal level, a joint effort of patients, 
physicians, nurses, and pharmacists is required. All patients 
should be advised to take the medicine only when sitting 
or standing, take water, and remain upright for at least an 
hour after administration.80 These warnings are of particular 
importance in elderly patients with dysphagia, or impaired 
mobility, such as bedridden patients. Several formulations 
based on NSAIDs are enteric-coated to reduce stomach 
irritation and minimize drug degradation. Also, in this case, 
crushing an enteric-coated medication exposes the GIT to 
the risk of irritation.
Tetracyclines
Antibacterials such as tetracycline and clindamycin are 
the offending agents in over 50% of the reported cases 
of drug-induced esophageal disorders.81 Drug-induced 
esophagitis caused by tetracycline or derivates is often mani-
fested in double-contrast studies by the development of small, 
discrete ulcers, typically in the mid-esophagus near the level 
of the aortic arch or left main bronchus.82 Crowson et al65 
treated three patients with esophageal ulceration associated 
with the ingestion of tetracycline or its derivative doxycycline, 
and found a strong temporal relationship between taking the 
capsules and the onset of the esophageal ulceration. They 
recommended an alternative to this class, when possible, for 
patients with any esophageal obstructive element, and advised 
patients not to take them within 1 hour of going to bed.
Gencosmanoglu et al83 described two different clinical 
patterns of esophageal injury induced by tetracycline or 
doxycycline, comparing these patterns with respect to 
demographic, endoscopic, and clinical characteristics of 
the patients. They analyzed 48 patients diagnosed with 
doxycycline- or tetracycline-induced esophageal injury 
who were divided into two groups according to the type 
and location of their esophageal lesions. They found that 
mid-esophageal ulceration was induced predominantly by 
doxycycline, whereas distal esophagitis was induced by 
tetracycline. This work highlighted that the type of tetracy-
clines taken by patients may provide physicians with some 
clues about the pattern of esophageal injury, because mid-
esophageal ulceration seems to be more frequently associated 
with doxycycline, and distal esophagitis candidiasis with 
other tetracyclines.
In another study, five cases of doxycycline-induced 
esophagitis with endoscopic images were reported.84 
The authors demonstrated a strong correlation between 
esophagitis and how the medicines were taken. Swallowing 
the medicine with a small amount of water and recumbent 
posture after ingestion were the main predisposing factors, 
especially in the case of potentially harmful medications 
such as tetracyclines.84
Legal and ethical considerations
In hospital geriatric units, compounding is very common, 
but recently, serious concerns have been raised about the 
safety of this practice, with legal and ethical ramifications. 
Like any medical activity, the administration of solid oral 
dosage forms to dysphagic patients is burdened by the pos-
sible materialization of unwanted events for the patient. Since 
any manipulation of a medicinal product that is not clearly 
described in the product instructions is an off-label use of 
the product, the prescriber becomes legally responsible for 
any adverse effect that may ensue.34,85 The off-label use of 
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medicines must be supported by documented scientific evi-
dence and requires the patient’s informed consent.86
The prescriber has an ethical responsibility to provide 
patients with the information they need to make free and 
conscious decisions about their health care. In the case of 
elderly patients, who generally tend to passively accept 
physicians’ proposals, such communication is an espe-
cially important part of the doctor–patient relationship. 
Doctors must explain in understandable terms the limits 
of the medical intervention and the possible consequences, 
describe the advantages and risks that could arise from the 
therapy, make it clear that manipulation of the dosage form 
of the medicine is an off-label use, and obtain the patient’s 
informed consent.
Obtaining informed consent may be complicated in geri-
atric patients, and even more so in dysphagic ones because 
of the clinical conditions linked to or responsible for the 
swallowing disorder. Additional issues may come from the 
coexistence of neurologic disorders or postoperative cogni-
tive dysfunction.17
These are the aspects of great ethical and professional 
interest in working with a segment of the population that 
is socially, physically, and mentally vulnerable.87 The legal 
ramifications of off-label use, the ethical requirements to 
explain in understandable terms to patient’s and to obtain 
informed consent from those who may have limited cognitive 
abilities pose a considerable challenge to prescribers.
Concluding remarks
The concomitant presence of different acute and chronic 
diseases in geriatric patients obliges physicians to prescribe a 
large number of medicines, most of which are sold as solid oral 
dosage forms; there is an almost complete absence of age-appro-
priate formulations that would allow personalization of therapy, 
especially in patients with dysphagia. Thus, HCPs in geriatric 
units or home care quite often manipulate solid formulations 
to facilitate their administration, a practice that in most cases 
is an off-label use of the medicine prescribed. Since the path 
to having geriatric tailored medicinal products on the market is 
neither simple nor short, physicians, in the absence of reliable 
alternatives, are obliged to prescribe solid oral dosage forms 
and advise their compounding in the hospital pharmacy.
However, before taking this hazardous route, alterna-
tive solutions and possible adverse events must be carefully 
evaluated. The prescriber should consider the possibility of 
substituting the solid with a liquid dosage form or of using 
alternative routes of administration in a case-by-case manner. 
If this is not feasible, the physician, in close collaboration 
with the pharmacist, should evaluate the risk-to-benefit 
ratio of administering a compounded marketed formulation. 
Pharmacists should have a pivotal role in this decision, since 
they have a solid background in biopharmaceutics, pharma-
ceutical technology, and drug delivery. In this evaluation, 
important factors to be taken into consideration are the 
formulation technology, especially whether the formulation 
is a modified-release form (which in most cases would 
exclude its manipulation), and whether the APIs have a nar-
row therapeutic window or are irritants for the GIT mucosa. 
If it is decided that the manipulation of a prolonged-release 
dosage form is truly necessary, the dose should be evalu-
ated carefully to avoid dose dumping. If the compounding 
of a gastro-resistant tablet or capsule has to be performed, 
particular attention should be paid to the reason/s for the 
presence of an enteric coating. Gastric mucosa irritation, 
drug inactivation in gastric fluids, and inconstant or limited 
absorption in the stomach are the possible motivations.
If the final decision is to compound a marketed formu-
lation, the prescriber should discuss this decision with the 
patient, describing the documented scientific evidence on 
the efficacy and safety of the off-label use of the drug (not 
very common in the literature), and must obtain informed 
consent. Then, a licensed physician or pharmacist, and not a 
nurse or another HCP, must perform compounding, assuring 
minimal API loss and the correctness of the dose in the 
compounded form.
Since the problem of oral therapy in geriatric dysphagic 
patients is not new, reputable institutions have issued guide-
lines on marketed product compounding.88–91 In the absence of 
published studies on the manipulation of a specific medicinal 
product, prescribers and pharmacists should refer to the 
general principles reported in them. Unfortunately, this issue 
receives minimal attention by the stakeholders and, only 
recently, regulatory agencies and academics are taking the 
first steps toward the development of age-appropriate geriatric 
medicinal products.59,92 In May 2011, the European Medical 
Agency’s Committee for Medicinal Products for Human Use 
established the Geriatric Expert Group to provide scientific 
advice on different matters related to geriatric medicines and 
gerontology. Among others, the Group has to provide advice 
on “specific geriatric aspects of medicine development, 
assessment of products or pharmacovigilance issues”.93
We sincerely hope that these actions will improve the qual-
ity aspects of medicines for older people and reduce the risks 
linked to the manipulation of marketed medicinal products.
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